PDCD1 and neoplasm: In the tumor growth delay study, after one course of the antibody Sindilizumab, MC38-hPD-L1 tumor and MC38-hPD-L1/KO tumor was suppressed, whereas an effect on PD-1 blockade efficacy was also observed on MC38-KO tumor.